EGFR and nasopharyngeal carcinoma: In a first‐in‐human dose‐escalation study (CTR20180310) involving patients with relapsed/refractory solid tumors, the DCR was 100% for EGFR‐positive patients receiving doses of MRG003 at or above 1.5 mg/kg.182 In a subset analysis from another phase I study (NCT04868344) involving 39 patients with refractory advanced squamous cell carcinomas of the head and neck, colorectal cancer, and nasopharyngeal carcinoma, all patients were found to be EGFR positive.183